Clinical Trial Update: Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating sorafenib for persistent or recurrent ovarian epithelial or peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Carcinoma
• Peritoneal Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED